Finoriq research workspace
Krystal Biotech, Inc. (KRYS) SEC Filings & Filing Highlights
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops. Review KRYS SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
- Company
- Krystal Biotech, Inc. (KRYS)
- Ticker
- KRYS
- Market Cap
- $10.1B
- Latest Price
- $341.71
- Industry
- Biotech & Pharma
Krystal Biotech, Inc. (KRYS) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Krystal Biotech, Inc. (KRYS).
| Event | Form | Date |
|---|---|---|
| Proposal One: Election of Class III DirectorsOn May 15, 2026, Krystal Biotech, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Set forth below... | 8-K5.07 | 2026-05-20 |
| Press Release, dated May 4, 2026Cover Page Interactive Data file (embedded within the Inline XBRL document) | 8-K9.01 | 2026-05-04 |
| Krystal Biotech Announces Fourth Quarter and Full Year 2025Krystal Biotech Announces Fourth Quarter and Full Year 2025 | 8-K2.02 | 2026-02-17 |
| The disclosure in Item 2.02 above is also being furnished under this Item 7.01The disclosure in Item 2.02 above is also being furnished under this Item 7.01 | 8-K7.01 | 2026-01-12 |
| Krystal Biotech, Inc.: Earnings or resultsOn January 11, 2026, Krystal Biotech, Inc., a Delaware corporation (the “Company”), issued a press release (the “Press Release”) in advance... | 8-K2.02 | 2026-01-12 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.